Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

WuXi’s New Unit Joins Race For Drug Innovation In China

This article was originally published in The Pink Sheet Daily

Executive Summary

WuXi is opening up its service platform, manufacturing capacity and pockets, aiming to develop global biotech innovations in China faster and cost-effectively. The strategy may draw on a template of a joint venture with MedImmune and a contract manufacturing deal for Ambrx already in place.

You may also be interested in...



Big Pharma CEOs Suggest Policy Changes As They Return To Beijing

Global CEOs of J&J, Pfizer, AbbVie and Takeda were among the top pharma executives attending the China Development Forum in its first in-person meeting in three years, and highlighted a number of pharma-related policy changes they would like to see in China. Meanwhile, a Japanese employee of Astellas has been detained in the country for alleged espionage.

Chinese Biopharma Tycoons Down But Not Out In Latest Global Billionaire Ranking

China continues to dominate the latest list of global billionaires and top execs from domestic pharma firms Hengrui and Hansoh ranked among the wealthiest overall in the country, along with the founder of vaccine maker Zhifei Bio. A number of top Chinese biopharma business executives also featured in the global top 100 billionaires list.

COVID Lessons Mean New Vaccine Approach Needed In China, Exec Says

CEO of Chinese vaccine developer BravoVax shares views with Scrip on pandemic lessons learned and new approaches needed to move forward.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS077386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel